<DOC>
	<DOC>NCT01420445</DOC>
	<brief_summary>The study will conduct with 4 comparative groups orally treated with YHD001 dose level 1(t.i.d.), YHD001 dose level 2(t.i.d.), pelargonium sidoides extract 9mL(t.i.d.) or Placebo for 7 days. The treatments will be assigned randomly to patients (n=116) with acute or chronic bronchitis.</brief_summary>
	<brief_title>Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis</brief_title>
	<detailed_description>The outcome measures is to evaluate the overall change from baseline to the end of treatment in scores relating to the severity of four symptom of bronchitis: cough, sputum, QOL of daily life, QOL of falling asleep at night.</detailed_description>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Bronchitis, Chronic</mesh_term>
	<criteria>Male and female patients aged ≥18 year Provision of written informed consent Acute bronchitis with a Bronchitis Severity Score(BSS)≥five points History of any clinically significant disease History of drug/chemical/alcohol abuse Use of antibiotics, antihistamine during the 7 days before administration of the investigational product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>